Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04610-4 Two early clinical studies of selective KRASG12D inhibitors show encouraging activity in advanced cancers with G12D mutations, signaling a transformative change in the treatment landscape for RAS-driven cancers with potential applications across tumor types and stages of disease. Read More
Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04609-x An autonomous clinical AI agent enhances decision-making through on-premise deployment and reliability metrics, achieving high diagnostic accuracy and selective autonomy. Read More
Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04644-8 In the phase 2 RIO trial, there was delayed viral rebound and resistance to broadly neutralizing antibodies 3BNC117-LS and 10-1074-LS in adult males living with HIV undergoing analytical treatment interruption, and initial reservoir sensitivity to autologous antibodies was associated with a longer time to rebound. Read More
Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04559-4 In a phase 1 trial evaluating GFH375, an oral, dual on–off binding KRAS G12D inhibitor, in patients with KRASG12D-mutated solid tumors, there was one treatment-related death, while most treatment-related adverse events were low-grade, and encouraging response rates were observed in non-small cell lung cancer and pancreatic cancer. …
First in a series on probabilistic forecasting for physical signals. Next: what happens when you roll the forecast forward more than one step. The post Your Model’s MSE Is Lying to You appeared first on Towards Data Science. Read More